Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

Nihon University74 enrolled

Overview

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Polypoidal Choroidal Vasculopathy

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Polypoidal choroidal vasculopathy * must have injection of Ranibizumab Exclusion Criteria: \-

Locations (1)

Surugadai Nihon university hospital

1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, Japan

Outcomes

Primary Outcomes

Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab

Time frame: a month after injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.